公开(公告)号：US20240358834A1

公开(公告)日：2024-10-31

申请号：US18648206

申请日：2024-04-26

申请人： THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

发明人： Donald L. Siegel ,  Michael C. Milone

IPC分类号： A61K39/00 ,  A61P35/02 ,  C07K14/725 ,  C07K16/28

CPC分类号： A61K39/464412 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/4632 ,  A61P35/02 ,  C07K14/7051 ,  C07K16/2803 ,  A61K2239/13 ,  A61K2239/28 ,  C07K2317/622

摘要： The present disclosure relates to antibodies, binding polypeptides, scFvs, and chimeric antigen receptors (CARs) specific for CD19, nucleic acids encoding the same, methods of treatments, and other methods or uses thereof.

公开(公告)号：US20240358754A1

公开(公告)日：2024-10-31

申请号：US18592234

申请日：2024-02-29

申请人： LEGEND BIOTECH USA INC. ,  JANSSEN BIOTECH, INC.

发明人： Nitin PATEL ,  Lida PACAUD ,  Yuhong QIU ,  Nikoletta LENDVAI ,  William DERAEDT ,  Jordan Mark SCHECTER ,  Ana Rute DE ASCENSAO SLAUGHTER ,  Carolina LONARDI

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28

CPC分类号： A61K35/17 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464417 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2878 ,  A61K2239/13 ,  A61K2239/21 ,  A61K2239/22 ,  A61K2239/38 ,  A61K2239/48

摘要： Provided herein are methods of treating a subject who has multiple myeloma and has received one to three prior treatment(s). Infusions of chimeric antigen receptor (CAR)-T cells comprising a CAR capable of specifically binding to an epitope of BCMA are administered to the subject.

公开(公告)号：US20240350544A1

公开(公告)日：2024-10-24

申请号：US18640982

申请日：2024-04-19

申请人： Takeda Pharmaceutical Company Limited

发明人： Michael Curley ,  Ertan Eryilmaz ,  Shawn Jennings ,  LeeAnn Talarico ,  Taylor Hickman ,  Christina Sheau Fen Wong ,  Kathryn Fraser ,  Haiqing Wang ,  Alessandra Piersigilli

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61K47/20 ,  A61K47/26 ,  A61K47/42 ,  A61P35/02 ,  C07K16/28

CPC分类号： A61K35/17 ,  A61K39/4613 ,  A61K39/4631 ,  A61K39/464416 ,  A61K47/20 ,  A61K47/26 ,  A61K47/42 ,  A61P35/02 ,  C07K16/2878 ,  A61K2239/13 ,  A61K2239/21 ,  A61K2239/25 ,  A61K2239/48 ,  C07K2317/565

摘要： This present invention relates to BCMA binders (e.g. antibodies) and chimeric antigen receptor (CAR) constructs comprising a BCMA antigen binding molecule. The BCMA binders specifically bind to BCMA. The present BCMA CARs further comprise a hinge region (e.g., CD28 hinge), a transmembrane domain, and one or more intracellular NK cell signalling domains. NK cells expressing a BCMA CAR has increased efficacy in killing cancer cells. Provided herein also include therapeutic uses of the BCMA binders and BCMA CARs.

公开(公告)号：US20240316104A1

公开(公告)日：2024-09-26

申请号：US18575715

申请日：2022-06-29

申请人： Flagship Pioneering Innovations V, iNC.

发明人： Darby Rye Schmidt ,  Niranjana Aditi Nagarajan ,  William Joseph Kaiser ,  Peter Joseph Gough ,  Sabin Dhakal ,  Alexis Benoit Hubaud

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/47 ,  C07K16/28 ,  C12N5/0783 ,  C12N9/12 ,  C12N15/63

CPC分类号： A61K35/17 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464468 ,  A61P35/00 ,  C07K14/4747 ,  C07K16/2818 ,  C07K16/2827 ,  C12N5/0638 ,  C12N9/12 ,  C12N15/63 ,  A61K2039/505 ,  A61K2239/13 ,  A61K2239/17 ,  A61K2239/21 ,  C12N2510/00 ,  C12Y207/11001

摘要： In certain aspects, the disclosure relates to an immune cell that has been engineered to comprise one or more heterologous polynucleotides that promote thanotransmission by the immune cell. The immune cell may also comprise one or more nucleic acid sequences that encode a chimeric antigen receptor (CAR). Methods of promoting thanotransmission, promoting immune response, and treating cancer using the engineered immune cells are also disclosed.

公开(公告)号：US20240316102A1

公开(公告)日：2024-09-26

申请号：US18573893

申请日：2022-06-30

申请人： Indapta Therapeutics, Inc.

发明人： Guy DIPIERRO ,  Austin BIGLEY

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/54 ,  C07K14/55 ,  C07K14/725 ,  C12N5/0783 ,  C12N15/86

CPC分类号： A61K35/17 ,  A61K39/4613 ,  A61K39/4631 ,  A61K39/464424 ,  A61P35/00 ,  C07K14/5443 ,  C07K14/55 ,  C07K14/7051 ,  C12N5/0646 ,  C12N15/86 ,  A61K2239/13 ,  A61K2239/21 ,  A61K2239/48 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03 ,  C12N2501/2302 ,  C12N2501/2312 ,  C12N2501/2315 ,  C12N2501/2318 ,  C12N2501/2321 ,  C12N2501/2327 ,  C12N2510/00 ,  C12N2740/15043

摘要： Provided herein are engineered Natural Killer (NK) cells deficient in expression of FcRγ chain (g-NK cells), and further comprising a recombinant chimeric antigen receptor (CAR) and compositions thereof. Also provided herein are compositions containing the engineered NK cells and methods of making and using the engineered NK cells.

公开(公告)号：US20240307442A1

公开(公告)日：2024-09-19

申请号：US18571062

申请日：2022-06-16

申请人： Innovative Cellular Therapeutics Holdings, Ltd. ,  Innovative Cellular Therapeutics, Inc.

发明人： Wei DING ,  Yang ZHAO ,  Guiting HAN ,  Yuzhe PENG ,  Xianyang JIANG ,  Zhiyuan CAO ,  Lei XIAO ,  Le TIAN

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61P37/04 ,  C07K16/28 ,  C12N9/64

CPC分类号： A61K35/17 ,  A61K39/001112 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464459 ,  A61K39/46446 ,  A61P37/04 ,  C07K16/2803 ,  C12N9/6408 ,  C12N9/641 ,  C12N9/6491 ,  A61K2239/13 ,  A61K2239/21 ,  A61K2239/22

摘要： Embodiments relate to a modified cell comprising a polynucleotide encoding an antigen binding molecule and a polynucleotide encoding an agent targeting one or more extracellular matrix (ECM) molecules. In embodiments, the polynucleotide encoding the agent comprises at least a nucleic acid encoding Cathepsin K (CK), a nucleic acid encoding Neutrophil Elastase (NE), or a nucleic acid encoding MMP7. In embodiments, the nucleic acid encoding NE comprises a nucleic acid encoding NE and a nucleic acid encoding a signaling domain of IL2. In embodiments, expression of the polynucleotide encoding the agent is regulated by hypoxia-inducible factor 1-alpha (HIF1α), nuclear factor of activated T-cells (NFAT), forkhead box P3 (FOXP3), or nuclear factor kappa B (NF-κB).

公开(公告)号：US20240301085A1

公开(公告)日：2024-09-12

申请号：US18275901

申请日：2022-02-09

申请人： SIMCERE ZAIMING PHARMACEUTICAL CO., LTD.

发明人： Hu GE ,  Shumei YOU

IPC分类号： C07K16/30 ,  A61K39/00 ,  G01N33/68

CPC分类号： C07K16/303 ,  A61K39/4631 ,  G01N33/6854 ,  A61K2039/505 ,  A61K2239/13 ,  A61K2239/21 ,  A61K2239/22 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/92

摘要： Provided is a humanized antibody or antigen-binding fragment that specifically binds to GPC3. The antibody or antigen-binding fragment has high affinity with GPC3 protein, and can be used in the preparation of drugs for treating tumors and the like. Also provided are a nucleic acid molecule encoding the humanized GPC3 antibody or antigen-binding fragment, an expression vector, a host cell, and a method for preparing the antibody or antigen-binding fragment. Also provided are an immunoconjugate comprising same, a chimeric antigen receptor, an immunocompetent cell, a multispecific molecule, and a pharmaceutical composition. Also provided are a method for detecting GPC3, and a method for treating various GPC3-related disorders including hepatocellular carcinoma.

公开(公告)号：US20240293453A1

公开(公告)日：2024-09-05

申请号：US17906040

申请日：2021-03-15

申请人： Janssen Biotech, Inc.

发明人： Patrick John DOONAN ,  Rajkumar GANESAN ,  Mehabaw Getahun DEREBE ,  Sathyadevi VENKATARAMANI ,  Sanjaya SINGH ,  Iqbal S. GREWAL ,  Karla R. WIEHAGEN

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61K47/68 ,  A61K51/10 ,  A61P35/00 ,  C07K14/725 ,  C07K16/28

CPC分类号： A61K35/17 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464411 ,  A61K47/6803 ,  A61K47/6849 ,  A61K51/1027 ,  A61K51/1096 ,  A61P35/00 ,  C07K14/7051 ,  C07K16/2803 ,  A61K2239/13 ,  A61K2239/17 ,  A61K2239/21 ,  C07K2317/22 ,  C07K2317/31 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2317/92 ,  C07K2319/31

摘要： The invention provides antigen binding domains that bind myeloid cell surface antigen CD33 protein comprising the antigen binding domains that bind CD33, polynucleotides encoding them, vectors, host cells, methods of making and using them.

公开(公告)号：US20240269182A1

公开(公告)日：2024-08-15

申请号：US18563764

申请日：2022-05-20

申请人： Innovative Cellular Therapeutics Holdings, Ltd. ,  Innovative Cellular Therapeutics, Inc.

发明人： CHENGFEI PU ,  WENSHENG WANG ,  XIAOGANG SHEN ,  LE TIAN

IPC分类号： A61K35/17 ,  A61K39/00 ,  C07K14/705 ,  C07K14/725 ,  C07K14/73 ,  C07K16/30

CPC分类号： A61K35/17 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464486 ,  C07K14/7051 ,  C07K14/70514 ,  C07K14/70517 ,  C07K16/30 ,  A61K2239/13 ,  A61K2239/21 ,  A61K2239/22 ,  A61K2239/57 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03

摘要： Embodiments of the present disclosure relate to a polynucleotide encoding a CAR comprising a cytoplasmic domain of CD4, or a CAR comprising SEQ ID NO: 17 in its intracellular domain, and the cytoplasmic domain of CD4 is located between a transmembrane domain of the CAR and a signaling or stimulatory domain, for example, CD3 zeta domain.

公开(公告)号：US20240216427A1

公开(公告)日：2024-07-04

申请号：US18270675

申请日：2021-12-29

申请人： St. Jude Children's Research Hospital, Inc.

发明人： Stephen GOTTSCHALK ,  Jessica WAGNER ,  Elizabeth WICKMAN ,  Timothy Isham SHAW ,  Jinghui ZHANG

IPC分类号： A61K35/17 ,  A61K39/00 ,  A61P35/02 ,  C07K14/705 ,  C07K14/725 ,  C07K16/18

CPC分类号： A61K35/17 ,  A61K39/4611 ,  A61K39/4631 ,  A61P35/02 ,  C07K14/7051 ,  C07K14/70521 ,  C07K16/18 ,  A61K2239/13 ,  A61K2239/21 ,  C07K2317/565 ,  C07K2317/622 ,  C07K2319/02 ,  C07K2319/03

摘要： The application provides chimeric antigen receptors (CARs) that target splice variants of the extracellular matrix proteins tenascin C (TNC) and procollagen 11A1 (Col11A1), and their uses in tumor immunotherapy. The application also provides polynucleotides and vectors that encode the chimeric antigen receptors, as well as host cells comprising the chimeric antigen receptors. The application also provides methods for preparing host cells comprising the chimeric antigen receptors and methods for treating patients using the modified host cells.